Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Immunology Right
  3. Taltz (ixekizumab) injection Right
  4. Has lymphoma been reported with Taltz® (ixekizumab)?
Search Taltz (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Taltz ® (ixekizumab) injection

80 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Has lymphoma been reported with Taltz® (ixekizumab)?

The incidence rate of lymphoma across 17 ixekizumab trials conducted in adult patients with plaque psoriasis was .03 per 100 patient-years as of March 2022.

US_cFAQ_IXE397_X1_TREATMENT_EMERGENT_LYMPHOMA_PsO_PsA_axSpA
US_cFAQ_IXE397_X1_TREATMENT_EMERGENT_LYMPHOMA_PsO_PsA_axSpA
en-US

Treatment-Emergent Malignancies Including Lymphoma in Psoriasis Clinical Trials

Across 17 pooled psoriasis trials conducted in adult patients (N=6892), accounting for 18,025.7 patient-years (PYs) of total ixekizumab exposure as of the March 2022 database lock, the treatment-emergent lymphomas reported based on Medical Dictionary for Regulatory Activities (MedDRA) preferred terms included

  • B-cell lymphoma (n=2, 0%)
  • diffuse large B-cell lymphoma (n=1, 0%)
  • Hodgkin's disease (n=1, 0%) 
  • Hodgkin's disease mixed cellularity stage unspecified (n=1, 0%), and
  • Non-Hodgkin's lymphoma (n=1, 0%).1

In the safety data set described previously, the incidence rate (IR) of overall malignancies was 0.8 per 100 PYs of exposure.2

Treatment-Emergent Malignancies Including Lymphoma in Psoriatic Arthritis Clinical Trials

Four pooled psoriatic arthritis trials (N=1401, accounting for 2247.7 PYs of total ixekizumab exposure as of the March 2022 database lock), reported no treatment-emergent lymphomas based on MedDRA preferred terms.1

In the safety data set described previously, the IR of overall malignancies was 0.7 per 100 PYs of exposure.2

Treatment-Emergent Malignancies Including Lymphoma in Axial Spondyloarthritis Trials

Four axial spondyloarthritis trials that include patients with ankylosing spondylitis/radiographic axial spondyloarthritis and nonradiographic axial spondyloarthritis (N=932, accounting for 2097.7 PYs of total ixekizumab exposure as of the March 2022 database lock), reported no treatment-emergent lymphomas based on MedDRA preferred terms.1

In the safety data set described previously, the IR of overall malignancies was 0.4 per 100 PYs of exposure.2

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Deodhar A, Blauvelt A, Schwartzman S, et al. Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis. Poster presented at: American College of Rheumatology/ARP - 2022 Annual Scientific Meeting; November 10-14, 2022; Philadelphia, Pennsylvania.

Date of Last Review: November 22, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly